Background Cannabidiol (CBD), a nonpsychoactive cannabinoid with a low toxicity profile,
has been shown to produce antitumor activity across cancers in part through selective …

Introduction: Glioblastoma (GBM) is the most common invasive brain tumor composed of
diverse cell types with poor prognosis. The highly complex tumor microenvironment (TME) …

Glioblastoma multiforme (GBM) is highly resistant to current anticancer treatments, which
makes it crucial to find new therapeutic strategies aimed at improving the poor prognosis of …

High-grade glioma is one of the most aggressive cancers in adult humans and long-term
survival rates are very low as standard treatments for glioma remain largely unsuccessful …

Simple Summary In glioblastoma (GBM), the highest-grade IV glioma, members of the large
membrane receptor family of G protein-coupled receptors (GPCRs) are upregulated …

In the present study, we found that CBD inhibited U87-MG and T98G cell proliferation and
invasiveness in vitro and caused a decrease in the expression of a set of proteins …

Evidence suggests that the nonpsychotropic cannabis-derived compound, cannabidiol
(CBD), has antineoplastic activity in multiple types of cancers, including glioblastoma …

Background: We previously reported that cannabidiol (CBD), a cannabinoid with a low
toxicity profile, downregulated the expression of the prometastatic gene inhibitor of DNA …

Despite advances in glioblastoma (GBM) therapy, prognosis of the disease remains poor
with a low survival rate. Cannabidiol (CBD) can induce cell death and enhance …

Cannabinoids possess a number of characteristics that make them putative anticancer
drugs, and their value as such is currently being explored in a number of clinical studies. To …